Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function
Authors:
- Reza KhosravanRKReza Khosravan
- JoAnn La FargueJFJoAnn La Fargue
- 1 April 2010
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 50 (4) , 472-481
Abstract
This phase I, open‐label, single‐dose study evaluates the effects of severe renal impairment and end‐stage renal disease (ESRD) requiring hemodialysis on the pharmacokinetics, safety, and tolerability of sunitinib and its primary active metabolite, SU12662. Subjects with normal renal function (creatinine clearance > 80 mL/min), severe renal impairment (creatinine clearance < 30 mL/min), and ESRD requiring hemodialysis receive a single dose of sunitinib 50 mg. Serial blood samples are collected for quantification of plasma concentrations using a validated liquid chromatography with tandem mass spectrometry assay. Safety is monitored. Twenty‐four subjects complete the study. Pharmacokinetics in subjects with severe renal impairment appear similar to those with normal renal function. Plasma exposure to sunitinib and SU12662 appears lower in subjects with ESRD compared with subjects with normal renal function or severe renal impairment. Single‐dose sunitinib 50 mg is well tolerated regardless of renal function. The currently approved starting dose of sunitinib 50 mg on Schedule 4/2 is expected to be appropriate for patients with renal impairment; any subsequent dose modifications should be based on patients' ability to tolerate treatment.Keywords
This publication has 19 references indexed in Scilit:
- Sunitinib in combination with docetaxel and prednisone in patients with metastatic hormone-refractory prostate cancer (mHRPC) - preliminary resultsJournal of Clinical Oncology, 2008
- Sunitinib monotherapy in patients with advanced hepatocellular carcinoma (HCC): Insights from a multidisciplinary phase II studyJournal of Clinical Oncology, 2008
- Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a TaxaneJournal of Clinical Oncology, 2008
- Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2008
- Phase II Trial of Sunitinib in Patients With Metastatic Colorectal Cancer After Failure of Standard TherapyJournal of Clinical Oncology, 2007
- A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activitiesAnnals of Oncology, 2007
- Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II studyJournal of Clinical Oncology, 2007
- An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer KinasesThe Journal of Clinical Endocrinology & Metabolism, 2006
- SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis modelClinical & Experimental Metastasis, 2003
- SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivoBlood, 2003